Eurofins, FR0014000MR3

Jefferies raises Eurofins target to EUR 62: Eurofins stock sits 0.72 percent below its high

Published on 10/27/2026 at 10:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Jefferies lifted its Eurofins target from EUR 58.00 to EUR 62.00 on October 26, 2026. Eurofins stock costs EUR 85.72 on October 27, 2026, 0.72 percent below its high.

Target and growth signals

  • Jefferies raised its Eurofins target from EUR 58.00 to EUR 62.00 on October 26, 2026.
  • Eurofins reported EUR 5.614 billion in nine-month revenue for 2026, up 3.7 percent year over year.
  • Eurofins stock trades at EUR 85.72 at 10:10 a.m. CEST at Lang & Schwarz on October 27, 2026.
Eurofins, FR0014000MR3, Illustration mit AI erstellt.

Eurofins Scientific stock (ISIN FR0014000MR3) was trading at EUR 85.72 at Lang & Schwarz on October 27, 2026, 0.72 percent below its 52-week high of EUR 86.34. On October 26, 2026, Zonebourse reported that Jefferies kept its underperform rating while raising its price target from EUR 58.00 to EUR 62.00.

Growth is improving unevenly

The latest operating update came on October 21, 2026. According to Eurofins, reported revenue reached EUR 5.614 billion in the first nine months of 2026, up 3.7 percent from the same period in 2025. Organic growth reached 3.0 percent, while third-quarter organic growth accelerated to 3.5 percent from 2.5 percent in the first quarter.

The trade-off is visible in the outlook. Eurofins said full-year 2026 organic growth would likely fall below its previous mid-single-digit objective, while its adjusted EBITDA margin is expected to improve from 22.5 percent in fiscal year 2025. The company retained its 24.00 percent adjusted EBITDA margin objective for 2027.

Three milestones and their figures

On October 2, 2026, Eurofins announced the completion of Element's North America Life Sciences Testing Services acquisition for an enterprise value of USD 400 million, while its Electrical and Electronic Testing business was sold for EUR 575 million, according to the company's investor page. On October 21, 2026, the nine-month update reported EUR 5.614 billion in revenue. On October 26, 2026, Jefferies raised its target from EUR 58.00 to EUR 62.00 while retaining an underperform rating.

What does the target change mean?

The revised EUR 62.00 target remains below the Lang & Schwarz quote of EUR 85.72, showing that the rating stance is more cautious than the price action. Eurofins' company-wide growth is also being supported by acquisitions: revenue from 2026 acquisitions is expected to exceed the previous annualized objective of EUR 250 million, according to Business Wire.

Next investor date is November 11

Eurofins lists its North America Investor Day in Toronto for November 11, 2026, according to its investor calendar. The event gives management a scheduled opportunity to explain how acquisitions, laboratory investments and margin expansion fit together.

Stock stays near its yearly high

Eurofins stock was trading at EUR 85.72 at Lang & Schwarz on October 27, 2026 at 10:10 a.m. CEST, 0.72 percent below its 52-week high of EUR 86.34.

The further course of trading is shown by the continuously updated real-time quote of Eurofins stock.

Eurofins stock facts

  • Company: Eurofins Scientific SE
  • ISIN: FR0014000MR3
  • Ticker: ERF
  • Primary exchange: Euronext Paris
  • Price Lang & Schwarz (as of October 27, 2026, 10:10 a.m. CEST): EUR 85.72
  • 52-week range: EUR 54.86-EUR 86.34
  • Market capitalization: EUR 14.9 billion (as of October 27, 2026)
  • Sector / Industry: Healthcare / Medical Diagnostics and Research
  • Index membership: CAC 40

Market context: Market report CAC 40.

More news and analyses on Eurofins stock

Disclaimer...
en | FR0014000MR3 | EUROFINS | boerse | 70418902 |